Development of Hbhac-Modified Infliximab with Transcytosis Ability for Inflammatory Bowel Disease by Oral Delivery System

2019-08-012024-05-14https://scholars.lib.ntu.edu.tw/handle/123456789/657874發炎性大腸疾病infliximab抗體藥物口服遞送穿胞胜肽inflammatory bowel diseaseinfliximabantibody drug oral deliverycell-penetrating peptideDevelopment of Hbhac-Modified Infliximab with Transcytosis Ability for Inflammatory Bowel Disease by Oral Delivery System